Recombinant humanized monoclonal antibody MIL95 (Mabworks/Connaught Biomedical Technology)

重组人源化单克隆抗体MIL95（天广实/康诺亚生物医药科技）

Report date: 2024/03/01 17:19:53

Base Information

Drug NameRecombinant humanized monoclonal antibody MIL95 (Mabworks/Connaught Biomedical Technology)
Drug Alias NameMIL-95CM-312
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursLymphomaLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Huafang Tianshi Biopharmaceutical Co LtdShanghai Lingyue Biomedical Technology Co LtdBeijing Mabworks Biotech Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphomaLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A